Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Single-blind Treatment

Respiratory Muscle Strength Training in Presbyphonia

Presbylarynx

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcome: Primary: Post-Treatment Mean in Voice Handicap Index Score — 15.00; 15.75; 18.50 score on a scale — p=0.041

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Inspiratory Muscle Strength Training (IMST) (Device); Expiratory Muscle Strength Training (EMST) (Device); Voice Exercises (Behavioral)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Medical University of South Carolina
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Post-Treatment Mean in Voice Handicap Index Score
15.00; 15.75; 18.50 0.041 sig
SECONDARY
Post-treatment Mean in (Habitual) Sound Pressure Level
73.18; 70.73; 74.75 0.887
SECONDARY
Post-treatment Mean in Baseline Smoothed Cepstral Peak Prominence (CPPS) (During Reading)
18.03; 16.74; 17.86 0.733
SECONDARY
Post-treatment Mean in Baseline Noise-to-harmonic Ratio (NHR)
0.13; 0.16; 0.12 0.702
SECONDARY
Post-Treatment Mean in Baseline Amplitude Perturbation Quotient (APQ)
2.91; 4.25; 3.05 0.198
SECONDARY
Post-treatment Mean in Overall Severity of Voice Quality
21.00; 31.25; 35.00 0.388
SECONDARY
Post-treatment Mean in Baseline Bowing Index
9.03; 5.76; 8.97 0.296
SECONDARY
Post-treatment Mean in Communicative Participation Item Bank (CPIB) Score
24.00; 19.50; 14.75 0.040 sig
SECONDARY
Post-treatment Mean in Glottal Function Index (GFI) Score
9.75; 8.75; 8.75 0.887
SECONDARY
Post-treatment Mean in Average Glottal Airflow
0.10; 0.27; 0.18 0.663
SECONDARY
Post-treatment Mean in Average Subglottal Pressure
6.37; 6.47; 5.99 0.026 sig
SECONDARY
Post-treatment Mean in Aerodynamic Resistance
63.43; 21.25; 37.11 0.721
SECONDARY
Post-treatment Mean in Maximum Expiratory Pressure (MEP)
121.00; 176.25; 131.00 0.408
SECONDARY
Post-treatment Mean in Maximum Inspiratory Pressure (MIP)
98.75; 84.50; 81.50 0.638
SECONDARY
Post-treatment Mean in Forced Vital Capacity (FVC)
80.75; 80.75; 94.00 0.715
SECONDARY
Post-treatment Mean in Forced Expiratory Volume in 1 Second (FEV1)
75.75; 73.00; 94.00 0.708
SECONDARY
Post-Treatment Mean for FEV1/FVC
94.00; 87.75; 99.00 0.988

Summary

Presbyphonia is an age-related voice disorder that affects more than 10 million people in the United States. Presbyphonia is characterized by vocal fold atrophy that impairs older individuals' ability to communicate, leading to social isolation and reduced quality of life. Outcomes from current treatment approaches are often suboptimal for patients with presbyphonia as they do not sufficiently challenge the respiratory system to induce meaningful change. It is highly likely that the addition of respiratory training would result in greatly improved outcomes, such as the ability to speak loud and long enough to have a normal conversation. The purpose of this study will be to examine the effect of adding inspiratory muscle strength training (IMST) or expiratory muscle strength training (EMST) to standard of care voice therapy on respiratory and voice outcomes in patients with an age-related voice disorder. Forty-eight participants diagnosed with presbyphonia will be blocked-randomized into three intervention groups, using a 3-parallel arm design: IMST and voice exercises, EMST and voice exercises, and voice exercises during all session. Study endpoints will be the change in voice and respiratory measures after four treatment sessions compared to baseline values. Response to treatment will be analyzed to determine if there are subgroups of high- or low-responders based on baseline voice and respiratory characteristics.

Eligibility Criteria

Inclusion Criteria

  • must receive a diagnosis of presbyphonia by a trained laryngologist. The diagnosis will be given following a visual examination if the observations are consistent with the characteristics of a presbylarynx, as judged by the laryngologist.
  • must be 50 years old and older.

Exclusion Criteria

  • has received voice therapy in the past year
  • presents with a vocal fold pathology other than presbyphonia
  • has a known neurologic or a progressive neuromuscular disease
  • has a medical condition that could be aggravated by the experimental intervention, or any condition judged by the physician (Dr. Halstead) as being unsuitable for RMST.
  • has dysarthria or a language disorder
  • has a hearing loss that is not adequately managed
  • has a cognitive disorder that might affect treatment compliance
  • is unable to give informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03557775). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search